Analysis Group Researchers to Present ISPOR Webinar on GenAI in HEOR
Event: Generative AI: Driving the Next Era of Evidence-Based Medicine Date: 10 December 2026 Host: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Times: 12:00–1:00 p.m. (EST)
Principal Jimmy Royer and Senior Data Scientists Intekhab Hossain and Esteban León will lead an ISPOR webinar on generative AI (GenAI) and its applications in health economics and outcomes research (HEOR) and real-world evidence (RWE) studies. The webinar will highlight how data from electronic medical records, disease registries, and population-based cohorts can be curated, linked, and powered with AI to generate insights that are both context-specific and globally relevant.
Analysis Group is pleased to sponsor the event as a corporate partner of ISPOR.
Associated People
Jimmy Royer
PrincipalDr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.